NCT02151786View on ClinicalTrials.gov

Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]

CompletedOBSERVATIONAL
Enrollment

1,120

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions
Interventions
DRUG

Lansoprazole

Lansoprazole intravenous 30 mg

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY